



GENFIT APPOINTS NEW VP FINANCE

Lille (France), Cambridge, MA (United States), December 17, 2007 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company committed to drug discovery and development in the field of cardiovascular, inflammatory and metabolic disease, today announced the appointment of Nathalie Huitorel as Vice-President, Finance. Stéphane Postic, company's Vice-President, Finance since 2000, is founding his own finance company but will continue to sit at the company's Supervisory Board.

Nathalie Huitorel has an outstanding record in integration and managing of multi-disciplinary environments including in-depth experience in organizational, financial, and operational functions.

A Lille Business School graduate, Huitorel (46) has previously worked in multiple operational functions in technology based companies. For the past 10 years, Huitorel has been the CFO of MS COMPOSITES, an aeronautical field leader specializing in high-performance materials. Previous to that, she was involved in listing of French company FINUCHEM on the stock market and has led numerous mergers and acquisitions.

Jean-François Mouney, CEO of GENFIT stated: "I would like to take this opportunity to thank Stéphane for the work that he has done for GENFIT since 2000 and wish him all the best in his new entrepreneurial endeavor. He remains closely linked with GENFIT and will stay on as a Supervisory Board Member. We are delighted to welcome Nathalie who is bringing her extensive experience to this key role."

About GENFIT:

A biopharmaceutical company, GENFIT studies the deregulation of genes implicated in the most widespread diseases. GENFIT's scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT's programs, conducted in partnership with pharmaceutical companies such as SANOFI-AVENTIS, PIERRE FABRE, FOURNIER (SOLVAY GROUP), MERCK AG, and SERVIER, treat the most prevalent metabolic and inflammatory diseases. GENFIT's development of proprietary drugs focuses on global cardiovascular risk, using a single molecule to simultaneously attack several pathologies (atherosclerosis, diabetes, obesity, etc.).

GENFIT possesses a rich and diversified pipeline of drug candidates in all stages of development - development carried out by GENFIT alone or in partnership. Four molecules are currently in Phase II: two 100% proprietary products and two molecules in partnership with SANOFI-AVENTIS (AVE8134 and AVE0847). In addition, another molecule in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I.

With facilities in Lille, France, and Cambridge, MA (USA), the company was founded by Jean-François Mouney, Chairman of the Management Board, with the scientific support of Jean-Charles Fruchart, Chairman of the Supervisory Board. It has more than 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). (www.genfit.com).

Contacts:

GENFIT

Jean-François Mouney - Chairman of the Management Board

+ 33 (0)3 20 16 40 00

MILESTONES – Press Relations

Bruno Arabian

+33 (0)1 70 08 04 13 / +33 (0)6 87 88 47 26 - milestones@milestones-fr.com

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus.